Patient-reported outcomes (PROs) are necessary to assess disease impacts from the patient’s perspective. In line with the Food and Drug Administration’s (FDA’s) guidance on PROs, the Depression and Family Functioning Scale (DFFS) was developed to assess the impact of major depressive disorder (MDD) on family functioning. Psychometric analyses were conducted to establish the reliability, validity, and responsiveness of the DFFS according to the FDA PRO guidance.
Validation of the Depression and Family Functioning Scale (Dffs)
Francois, C., Danchenko, N., Williams, V., Nelsen, L., Yarr, S., DiBenedetti, D., & Lancon, C. (2015). Validation of the Depression and Family Functioning Scale (Dffs). Value in Health, 18(3), A24-A24. https://doi.org/10.1016/j.jval.2015.03.150
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Rate of onset of dopamine transporter inhibitors assessed with intracranial self-stimulation and in vivo dopamine photometry in rats
Personal exposure to PM2.5 in different microenvironments and activities for retired adults in two megacities, China
Estimating global artisanal fishing fleet responses in an era of rapid climate and economic change